BSX

Boston Scientific Corp

Add to Watchlist

Advanced Chart

106.760

+0.29(0.272%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

107.230

Open

106.460

VWAP

106.59

Vol

7.17M

Mkt Cap

157.95B

Low

105.880

Amount

763.81M

EV/EBITDA(TTM)

34.92

Total Shares

1.47B

168.76B

EV/OCF(TTM)

P/S(TTM)

8.61

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

5.17B

+10.8%

0.780

+3.97%

5.16B

+13.15%

0.764

+9.13%

4.96B

+17.74%

0.713

+13.2%

Estimates Revision

The market is revising Upward the revenue expectations for Boston Scientific Corporation (BSX) for FY2025, with the revenue forecasts being adjusted by 0.04% over the past three months. During the same period, the stock price has changed by 3.46%.

Revenue Estimates for FY2025

Revise Upward

+0.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.3%

In Past 3 Month

Stock Price

Go Up

+3.46%

In Past 3 Month

22 Analyst Rating

11.87% Upside

Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 119.43 USD with a low forecast of 110.00 USD and a high forecast of 135.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

21 Buy

1 Hold

0 Sell

Strong Buy

11.87% Upside

Current: 106.760

Low

110.00

Averages

119.43

High

135.00

11.87% Upside

Current: 106.760

Low

110.00

Averages

119.43

High

135.00

Canaccord

William Plovanic

Hold

maintain

$75 -> $81

2025-07-25

Reason

Canaccord

William Plovanic

Price Target

$75 -> $81

2025-07-25

maintain

Hold

Reason

Canaccord analyst William Plovanic raised the firm's price target on Edwards Lifesciences (EW) to $81 from $75 and keeps a Hold rating on the shares. The firm said while the revenue and TAVR beat made for agood headline, the details leave their thesis unchanged. The revenue beat was mostly driven by TAVR, which they believe was due to OUS contributions, including taking share from Bsoton Scientific (BSX); who recently left the market, and Japan returning to growth.

Barclays

NULL -> Overweight

maintain

$125 -> $133

2025-07-24

Reason

Barclays

Price Target

$125 -> $133

2025-07-24

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Boston Scientific to $133 from $125 and keeps an Overweight rating on the shares. The company reported a Q2 beat on strong growth in Watchman and Farapulse, the analyst tells investors in a research note. The firm increased estimates post the report.

Wells Fargo

Larry Biegelsen

Overweight

maintain

$118 -> $124

2025-07-24

Reason

Wells Fargo

Larry Biegelsen

Price Target

$118 -> $124

2025-07-24

maintain

Overweight

Reason

Wells Fargo analyst Larry Biegelsen raised the firm's price target on Boston Scientific to $124 from $118 and keeps an Overweight rating on the shares. The firm says Boston Scientific reported Q2 revenue/EPS ahead of Street on strong PFA and Watchman strength. It raised 2025 organic growth guidance to 14%-15% and EPS guidance to $2.95-$2.99.

UBS

Buy

maintain

$130 -> $135

2025-07-24

Reason

UBS

Price Target

$130 -> $135

2025-07-24

maintain

Buy

Reason

UBS raised the firm's price target on Boston Scientific to $135 from $130 and keeps a Buy rating on the shares. Boston Scientific again exceeded expectations as the company continues to benefit from the most positive product cycle in all of large-cap MedTech, with an organic sales and EPS growth quarter above consensus, the analyst tells investors in a research note. Operational strength continues to drive outperformance, UBS adds.

Baird

Outperform

maintain

$117 -> $123

2025-07-24

Reason

Baird

Price Target

$117 -> $123

2025-07-24

maintain

Outperform

Reason

Baird raised the firm's price target on Boston Scientific to $123 from $117 and keeps an Outperform rating on the shares. The firm updated its guidance following its beat and raise Q2 results which increased conviction as a best-in-class growth stock. Boston Scientific remains a top idea.

Oppenheimer

Steven Lichtman

Outperform

maintain

$110 -> $118

2025-07-24

Reason

Oppenheimer

Steven Lichtman

Price Target

$110 -> $118

2025-07-24

maintain

Outperform

Reason

Oppenheimer analyst Steven Lichtman raised the firm's price target on Boston Scientific to $118 from $110 and keeps an Outperform rating on the shares. The firm says that Q2 sales of $5.06B beat its/Street's $4.9B estimates and EPS of 75c were ahead its/Street's 73c, led by the revenue beat, partially offset by ACURATE inventory charges following the May decision to discontinue the platform.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Boston Scientific Corp (BSX.N) is 34.25, compared to its 5-year average forward P/E of 26.70. For a more detailed relative valuation and DCF analysis to assess Boston Scientific Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Overvalued

5Y Average PE

26.70

Current PE

34.25

Overvalued PE

30.92

Undervalued PE

22.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

21.07

Current EV/EBITDA

27.28

Overvalued EV/EBITDA

24.54

Undervalued EV/EBITDA

17.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

5.50

Current PS

7.50

Overvalued PS

6.60

Undervalued PS

4.39

Financials

Annual

Quarterly

FY2025Q2

YoY :

+22.84%

5.06B

Total Revenue

FY2025Q2

YoY :

+3.86%

942.00M

Operating Profit

FY2025Q2

YoY :

+146.89%

795.00M

Net Income after Tax

FY2025Q2

YoY :

+140.91%

0.53

EPS - Diluted

FY2025Q1

YoY :

-443.21%

278.00M

Free Cash Flow

FY2025Q2

YoY :

-1.79%

62.93

Gross Profit Margin - %

FY2025Q2

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q2

YoY :

+100.90%

15.71

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

43.1M

USD

3-6

Months

17.4M

USD

6-9

Months

20.5M

USD

0-12

Months

60.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

4.5K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

12.6K

Volume

3-6

Months

2.8M

Volume

6-9

Months

1.6M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.4M

Volume

Months

6-9

4.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

97.0K

USD

3-6

Months

48.0K

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

8.0K

USD

Months

6-9

16.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

43.1M

USD

3-6

Months

17.4M

USD

6-9

Months

20.5M

USD

0-12

Months

60.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

4.5K

USD

Months

0-12

0.0

USD

Months

BSX News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

06:35:19

Boston Scientific raises FY25 EPS view to $2.95-$2.99 from $2.87-$2.94

2025-07-23

06:33:09

Boston Scientific sees Q3 adjusted EPS 70c-72c, consensus 70c

2025-07-23

06:31:53

Boston Scientific reports Q2 adjusted EPS 75c, consensus 73c

News

9.5

07-29NASDAQ.COM

Ecolab Stock Down in Pre-Market Post Q2 Earnings Miss, Margins Expand

7.0

07-25Benzinga

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

5.0

07-25Yahoo Finance

Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic